GlassScriptPhysician profile
Andrea Thomas
NPI 1821710799
$6,011.75
in general payments reported to CMS, 2019-2025
36 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.92 · 2023: $2,226 · 2024: $2,157 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,256 · Travel and Lodging: $2,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,256.35 |
| Travel and Lodging | $2,743.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $3,836.98 | 2023-2025 | Atricure Cryoice Cryoablation System (Cryo2), Synergy Ablation System, Atriclip Laa Exclusion System |
| Scpharmaceuticals INC. | $304.91 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $169.21 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $163.89 | 2023-2025 | Lifevest |
| Abbott Laboratories | $124.92 | 2025 | Cardiomems |
| Abiomed | $123.93 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $99.81 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $99.49 | 2023-2024 | Uptravi, Opsumit |
| Boston Scientific Corporation | $87.43 | 2023-2024 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $79.52 | 2023-2024 | Repatha, Tezspire |
| Harmony Biosciences LLC | $76.13 | 2023-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.62 | 2023-2024 | Jardiance, Ofev |
| Conetic Solutions, INC. | $69.44 | 2023-2025 | |
| Edwards Lifesciences Corporation | $67.25 | 2023-2024 | Hemosphere |
| Astrazeneca Pharmaceuticals LP | $61.68 | 2024 | Fasenra, Wainua |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50.11 | 2023-2024 | |
| Grifols USA, LLC | $47.21 | 2023-2024 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $42.36 | 2023-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $39.98 | 2024-2025 | Glassia |
| Bridgebio Pharma, INC. | $38.89 | 2025 | Attruby |
| Jazz Pharmaceuticals INC. | $35.51 | 2024-2025 | |
| Vifor Pharma, INC. | $34.83 | 2025 | Zemaira |
| Daiichi Sankyo INC. | $33.71 | 2022-2023 | Injectafer |
| Avadel Cns Pharmaceuticals, LLC | $32.34 | 2023-2025 | Lumryz |
| Alnylam Pharmaceuticals INC. | $26.92 | 2025 | Onpattro |
| Genzyme Corporation | $26.46 | 2024 | |
| Philips North America LLC | $20.37 | 2024 | (Ak6) Vest Therapy |
| Verona Pharma, INC. | $19.42 | 2025 | Ohtuvayre |
| Liquidia Technologies, INC. | $19.13 | 2025 | Yutrepia |
| Zoll Respicardia, INC. | $16.81 | 2024 | Remede System |
| Merck Sharp & Dohme LLC | $16.70 | 2024 | Verquvo |
| Medtronic, INC. | $16.18 | 2025 | Corevalve Evolut R |
| Glaxosmithkline, LLC. | $15.37 | 2024 | Nucala |
| Bayer Healthcare Pharmaceuticals INC. | $14.01 | 2025 | |
| United Therapeutics Corporation | $13.84 | 2023 | Tyvaso, Orenitram |
| Regeneron Healthcare Solutions, INC. | $13.39 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.